Merck & Co Inc

NYSE:MRK   3:59:59 PM EDT
92.50
+0.61 (+0.66%)
4:04:31 PM EDT: $92.75 +0.25 (+0.27%)
Products

FDA Approves Merck's Vaxneuvance For Invasive Pneumococcal Disease Prevention In Infants And Children

Published: 06/22/2022 11:26 GMT
Merck & Co Inc (MRK) - U.S. FDA Approves Merck’s Vaxneuvance™ (pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children.
Merck & Co Inc- U.S. Cdc Acip is Expected to Meet Today to Discuss and Make Recommendations on Use of Vaxneuvance in Pediatric Populations.
Merck & Co Inc- U.S. FDA Has Approved an Expanded Indication for Vaxneuvance to Include Children 6 Weeks Through 17 Years of Age.